Wide Ranks

CLDX

Celldex Therapeutics, Inc.

27.89

Top Statistics
Market Cap 1 B Forward PE -8.38 Revenue Growth 110.30 %
Current Ratio 24.27 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -6.42 Enterprise / Revenue 110.01 Price To Sales Trailing12 Months 185.48
Profitability
Profit Margins 0.00 % Operating Margins -1633.53 %
Balance Sheet
Total Cash 755 M Total Cash Per Share 11.39 Total Debt 3 M
Total Debt To Equity 0.3930 Current Ratio 24.27 Book Value Per Share 11.85
All Measures
Short Ratio 753.00 % Message Board Id finmb_9620565 Fax 908 454 1911
Shares Short Prior Month 8 M Return On Equity -0.2984 City Hampton
Uuid 467427db-31ce-3688-87cf-dec0758b5a4b Previous Close 26.76 First Trade Date Epoch Utc 516 M
Book Value 11.85 Beta 1.59 Total Debt 3 M
Volume 718318 Price To Book 2.35 Last Split Date 1 B
Fifty Two Week Low 22.93 Total Cash Per Share 11.39 Total Revenue 9 M
Shares Short Previous Month Date 1 B Target Median Price 69.00 Max Age 86400
Recommendation Mean 1.42 Sand P52 Week Change 0.3133 Operating Margins -1633.53 %
Target Mean Price 67.10 Net Income To Common -154076992 Short Percent Of Float 0.1366
Implied Shares Outstanding 66 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 1 M Average Volume10days 1 M Total Cash 755 M
Next Fiscal Year End 1 B Revenue Per Share 0.1640 Held Percent Insiders 0.0030
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 26.76 Target Low Price 42.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 29.35 Open 26.99 Free Cashflow -83732248
State NJ Dividend Yield 0.00 % Return On Assets -0.1973
Time Zone Short Name EST Trailing Eps -2.58 Day Low 26.94
Address1 Perryville III Building Shares Outstanding 66 M Price Hint 2
Target High Price 90.00 Website https://www.celldex.com 52 Week Change -0.0768
Average Volume 1 M Forward Eps -3.23 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 2358.30 % Last Split Factor 1:15
Regular Market Day High 28.19 Is_sp_500 False Profit Margins 0.00 %
Debt To Equity 0.3930 Fifty Two Week High 53.18 Day High 28.19
Shares Short 7 M Regular Market Open 26.99 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 110.01 Revenue Growth 110.30 %
Shares Percent Shares Out 0.1181 Operating Cashflow -157835008 Currency USD
Time Zone Full Name America/New_York Market Cap 1 B Is_nasdaq_100 False
Zip 08827 Quote Type EQUITY Industry Biotechnology
Long Name Celldex Therapeutics, Inc. Regular Market Day Low 26.94 Held Percent Institutions 1.10
Current Price 27.89 Address2 Suite 220 53 Frontage Road Enterprise To Ebitda -6.42
Financial Currency USD Current Ratio 24.27 Industry Disp Biotechnology
Number Of Analyst Opinions 10 Country United States Float Shares 66 M
Two Hundred Day Average 36.68 Ir Website http://www.avantimmune.com/ Enterprise Value 1 B
Price To Sales Trailing12 Months 185.48 Forward PE -8.38 Regular Market Volume 718318
Ebitda -171060992 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.

Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity.

It has research collaboration and license agreements with Yale University.

The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.